Exelixis - Recruiting 18 years or older. - A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.
Bayer - Recruiting 18 years or older. - An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer.
Centre Hospitalier Universitaire de NÄ«mes - Recruiting 45 years to 75 years. - Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy.
Bayer - Recruiting 18 years or older. - A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks.
Bayer - Recruiting 18 years or older. - A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years. - Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
Bayer - Recruiting 20 years or older. - A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases.
Bayer - Recruiting 18 years or older. - A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination With Abiraterone Acetate or Enzalutamide in Subjects With CRPC Who Have Bone Metastases.
New York University School of Medicine - Recruiting 18 years or older. - Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer.
Exelixis - Recruiting 18 years or older. - A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Nave Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer.